期刊文献+

甘露糖修饰壳聚糖对巨噬细胞摄取纳米粒的影响 被引量:3

Effects of Mannose Modified Chitosan on the Macrophage Uptake of Nanoparticles
原文传递
导出
摘要 目的制备和评价甘露糖修饰壳聚糖包衣乳酸-羟基乙酸共聚物(PLGA)纳米粒,考察其对巨噬细胞毒性和对巨噬摄取功能的影响。方法采用复乳法制备负载卵清蛋白(OVA)的PLGA纳米粒,并经甘露糖修饰壳聚糖包衣处理后用激光粒度测定仪测定该纳米粒的大小与ζ电位,透射电镜观察纳米粒的外观形态,BCA法测定OVA含量后计算载药量与释放度。负载异硫氰酸荧光素(FITC)标记的OVA纳米粒与巨噬细胞(RAW 264.7)共孵育,MTT法测定细胞存活率,荧光显微镜考察摄取程度。结果 OVA-PLGA纳米粒的大小和ζ电位均随壳聚糖包衣液浓度的增加而变大(P<0.05),OVA载药量范围为7.2%~8.4%。壳聚糖与甘露糖修饰壳聚糖包衣FITC-OVA-PLGA纳米粒与RAW 264.7共孵育后,对细胞存活率的影响不大(P>0.05),但可明显促进FITC-OVA-PLGA纳米粒的巨噬细胞摄取(P<0.05)。结论初步建立了负载模型抗原的甘露糖修饰阳离子型纳米粒系统,这为体内抗原递呈细胞靶向性研究提供了依据。 Objective To prepare and evaluate mannose modified chitosan(Man-CS) coated poly lactic-co-glycolic acid(PLGA) nanoparticles(NPs),observe its cytotocity and effects on the uptake of macrophages.Method Ovalbumin(OVA) loaded PLGA NPs were prepared by double emulsion method and coated with CS or Man-CS.The size and zeta potentional of NPs were detected by a laser particle size analyzer,BCA method was used to measure OVA concentration and calculate the drug loading and release rate.The cytotocixty and phagocytosis of FITC-OVA loaded NPs were investigated by MTT method and fluorescence microscope after incubating with macrophage cells(RAW 264.7).Results Both of the particle sizes and zeta potentionals of the OVA-PLGA nanoparticles increased with increasing the concentration of CS,and the loading amount of OVA was in the range of 7.2%~8.4%.No significant cytotoxicity was observed after incubating CS or Man-CS coating FITC-OVA-PLGA nanoparticles with RAW 264.7(P0.05) but noticeable phagocytosis effects were obtained(P0.05).Conclusions The model antigen loaded cationic nanoparticles modified with mannose-chitosan are prepared and it will provide evidences for the rsearch of antigen presentation cell targeting delivery systems.
出处 《苏州大学学报(医学版)》 CAS 北大核心 2011年第4期613-617,共5页 Suzhou University Journal of Medical Science
关键词 甘露糖受体 壳聚糖 乳酸-羟基乙酸共聚物 巨噬细胞 mannose receptor chitosan poly lactic-co-glycolic acid macrophage
  • 相关文献

参考文献10

  • 1Alizadeh D, Zhang LY, Hwang JY, et al. Tumor-associat- ed macrophages are predominant carriers of cyclodextrin- based nanoparticles into gliomas [ J ]. Nanomedicine : Nano- technology, Biology, and Medicine, 2010, 6 ( 2 ) : 382 - 390.
  • 2Jhunjhunwala S, Raimondi G, Thomson AW, et al. Deliv- ery of rapamycin to dendritic cells using degradable micro- particles [ J ]. Journal of Controlled Release, 2009, 133 (3) :191 - 197.
  • 3石艳,张惠斌,宗莉.靶向甘露糖受体的载体甘露糖化壳聚糖的全合成及其细胞毒性评价[J].药物生物技术,2009,16(3):207-211. 被引量:4
  • 4Soma CE, Dubernet C, Barratt G, et al. Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro [ J]. Journal of Controlled Release, 2000,68 ( 2 ) : 283 - 289.
  • 5Waeckerle-Men Y, Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vac- cines [ J]. Advanced Drug Delivery Reviews, 2005, 57 ( 3 ) : 475 - 482.
  • 6Jiang Hu-Lin, Kang Mi-Lan, Quan Ji-Shan, et al. The po- tential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery sys- tem for intranasal immunization [ J ]. Biomaterials, 2008, 29(12) : 1931 - 1939.
  • 7Yeeprae W, Kawakami S, Yamashita F, et al. Effect of mannose density on mannose receptor-mediated cellular up- take of mannosylated O/W emulsions by macrophages [ J ]. Journal of Controlled Release, 2006, 114 (2) : 193 - 201.
  • 8Zhou Xianfeng, Liu Bin, Yu Xianghui, et al. Controlled release of PEI/DNA complexes from mannose-bearing chi- tosan microspheres as a potent delivery system to enhance immune response to HBV DNA vaccine [ J ]. Journal of Controlled Release, 2007, 121 (3) : 200 - 207.
  • 9McConnell EL, Basit AW, Murdan S. Colonic antigen ad- ministration induces significantly higher humoral levels of colonic and vaginal IgA, and serum IgG compared to oral administration[ J ]. Vaccine, 2008, 26 (5) : 639 - 646.
  • 10Sharma G, Valenta DT, Altman Y, et al. Polymer pani- cle shape independently influences binding and internali- zation by macrophages [ J ]. Journal of Controlled Re- lease, 2010,147 (3) :408 - 412.

二级参考文献16

  • 1Wileman TE, Lennartz MR, Stahl PD, et al. Identification of the macrophage mannose receptor as a 175 - kDa membrane protein[J]. Proc Natl Acad Sci USA, 1986, 83 (8) :2501.
  • 2Stahl PD, Schulesinger PH, Singardson E, et al. Receptormediated pinoeytosis of mannose glycoconjugates by macrophages: characterization and evidence for receptor recycling [J]. Cell, 1980,19(1):207.
  • 3Sandra SD, Christian P, Matt C,et al. Mannose Receptor- Mediated Gene Delivery into Antigen Presenting Dendritic Cells [J]. Somatic Cell and Molecular Genetics, 2002, 27:65.
  • 4Lam JS, Mansour MK, Specht CA, et al. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity[J]. J Immunol, 2005,175 (11) : 7496.
  • 5Jiang H L, Kang M L, Quan, J S, et al. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization [J]. Biornaterials, 2008,29 : 1931.
  • 6Ferkol T, Perales J C, Mularo F, et al. Receptor-mediated gene transfer into macrophage [J]. Proc Natl Acad Sci USA, 1996,93:101.
  • 7Kawakami S, Sato A, Nishikawa M, et al. Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes [J]. Gene Therapy, 2000, 7:292.
  • 8Hirano S, Seino H, Akiyama Y, et al. Biocompatibility of chitosan by oral and intravenous administration [J]. Polym Mat Eng Sci, 1988,59:897.
  • 9KimTH, Hua J, HyunWK, etal. Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/cmice bearing CT-26 eardnoma ceils [J]. MolCancer Ther, 2006,5(7):1723.
  • 10Mayu H, Minoru M, Hiroyuki S, et al. Gene transfer by DNA/mannosylated ehitosan complexes into mouse peritoneal maerophages [J]. Biotechnol Lett, 2006,28(11) :815.

共引文献3

同被引文献58

  • 1田维毅,董登祥,杨娟,王平,王文佳.巨噬细胞甘露糖受体结合物筛选模型的初步建立[J].免疫学杂志,2009,25(5):500-504. 被引量:5
  • 2侯丽娜,赵鲁杭.壳寡糖结合并激活巨噬细胞机制的研究[J].中国医科大学学报,2006,35(2):124-127. 被引量:18
  • 3Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuramini dase inhibitor zanamivir in the treatment of influenza virus infections[ J]. N Engl J Med , 1997, 337 (13) :874 -880.
  • 4Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza [ J ]. Antiviral Res, 2008,7( 1 ) :9t - 102.
  • 5Escuret V, Frobert E, Bouscambert-Duchamp M, et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors [ J ]. J Clin Virol, 2008, 41( 1 ): 25-28.
  • 6Freitas C, Muller R. Correlation between long - term stabili- ty of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase [J]. Eur J Pharm, 1999, 47(2) : 125 -132.
  • 7Lv QZ, Yua AH, Yd YW, et al. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical de- livery[J]. Int J Pharm, 2009,372(1/2) :191 -198.
  • 8Allen GD, Brookes ST, Barrow A, et al. Liquid chromato- graphic-tandem mass spectrometric method for the determi- nation of the neuraminidase inhibitor zanamivir ( GG167 ) in human serum [ J ]. J Chromatogr B, 1999, 732 (2) : 383 - 393.
  • 9STAHL P D,EZEKOWITZ R A B.The mannose receptor is a pattern recognition receptor involved in host defense[J].Curr Opin Immunol, 1998 (10) :50-55.
  • 10TAYLOR P R,GORDON S,MARTINEZ P L.The mannose receptor: linking homeostasis and immunity through sugar recognition [J].Trends Immuno1,2005,26(2) : 104-110.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部